Clinical Trials Logo

Brain Tumor, Primary clinical trials

View clinical trials related to Brain Tumor, Primary.

Filter by:

NCT ID: NCT06322342 Recruiting - Multiple Sclerosis Clinical Trials

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.

NCT ID: NCT06282562 Recruiting - Exercise Clinical Trials

FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients

FeelFit
Start date: March 2024
Phase: N/A
Study type: Interventional

The FeelFit study aims to assess the effectiveness of High-Intensity Interval Training (HIIT) in improving self-reported physical fitness in adult brain tumor patients during periods of stable disease, as compared to a waiting-list control group. Furthermore, several secondary and exploratory outcomes will be evaluated. The study is part of the GRIP (GuaRding quality survivorshiP) project, which aims to improve quality of life in brain tumor patients.

NCT ID: NCT06185686 Not yet recruiting - Clinical trials for Brain Tumor, Primary

Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

Start date: June 30, 2024
Phase:
Study type: Observational

With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitive deficits being the primary obstacle to independent living. Robust predictors of cognitive decline and a comprehensive understanding of the underlying mechanisms of cognitive injury remain elusive. This study will prospectively investigate alterations in brain resting state networks following radiation therapy using functional imaging. The hypothesis is that radiation therapy leads to dose-dependent alterations in functional connectivity in the networks associated with higher level cognition, ultimately leading to cognitive decline.

NCT ID: NCT06106997 Not yet recruiting - Clinical trials for Brain Tumor, Primary

Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow

Start date: January 2024
Phase: N/A
Study type: Interventional

The goal of this observational study is to show the feasibility of an MRI-only workflow in brain radiotherapy. The main question it aims to answer is: - Is an MRI-only workflow based on deep learning sCTs feasible in clinical routine? Participants will be treated as in clinical routine, but treatment planning will be based on sCTs, that are generated from MRI images. The dosimetrical equivalence to the standard CT based workflow will be tested at several points in the study.

NCT ID: NCT06057168 Recruiting - Clinical trials for Brain Tumor, Recurrent

Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas

GDX-44-016
Start date: September 7, 2023
Phase: Phase 3
Study type: Interventional

This trial aims to study the performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.

NCT ID: NCT05831631 Recruiting - Clinical trials for Brain Tumor, Primary

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Start date: August 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.

NCT ID: NCT05775458 Recruiting - Clinical trials for Brain Tumor, Primary

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology

Start date: June 1, 2020
Phase:
Study type: Observational

Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. It is essential for regulating cellular metabolism and developmental synaptogenesis, cellular migration, differentiation and death. Recent scientific evidences have demonstrated alteration in Glu synthesis and signaling being directly involved in GBM growth and invasion

NCT ID: NCT05480644 Recruiting - Clinical trials for Brain Metastases, Adult

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors

Start date: December 1, 2022
Phase:
Study type: Observational

The purpose of this protocol is to create a repository of blood samples from patients diagnosed with primary and metastatic brain tumors who are being seen in the Department of Radiation Oncology at Duke Cancer Center.

NCT ID: NCT05254197 Recruiting - Meningioma Clinical Trials

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

SOLOMON
Start date: January 1, 2001
Phase:
Study type: Observational [Patient Registry]

The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.

NCT ID: NCT05092802 Recruiting - Clinical trials for Brain Tumor, Primary

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Start date: December 23, 2021
Phase: Phase 2
Study type: Interventional

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation